David T. Rubin

David T. Rubin

Gastroenterology | Hepatology

400 Skokie Blvd.
Suite 300
Northbrook, IL 60062

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 553 publications

End-to-Side Ileocolonic Anastomosis After Ileocecectomy for Crohn's Disease Is a Safe Option With Low Recurrence.

End-to-Side Ileocolonic Anastomosis After Ileocecectomy for Crohn's Disease Is a Safe Option With Low Recurrence.

Journal: Diseases of the colon and rectum

Published: June 16, 2026

Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensus.

Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensus.

Journal: Journal of Crohn's & colitis

Published: May 20, 2026

Mirikizumab is associated with rapid and sustained improvements in novel measures of bowel urgency in moderately-to-severely active ulcerative colitis: 28-week results from the LUCENT-URGE trial.

Mirikizumab is associated with rapid and sustained improvements in novel measures of bowel urgency in moderately-to-severely active ulcerative colitis: 28-week results from the LUCENT-URGE trial.

Journal: Journal of Crohn's & colitis

Published: May 11, 2026

Patient-Reported Outcomes in Clinical Trials of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Patient-Reported Outcomes in Clinical Trials of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: April 01, 2026

The efficacy and safety of etrasimod as a first-line advanced therapy for ulcerative colitis: prespecified and post hoc subgroup data from the ELEVATE UC clinical program.

The efficacy and safety of etrasimod as a first-line advanced therapy for ulcerative colitis: prespecified and post hoc subgroup data from the ELEVATE UC clinical program.

Journal: Therapeutic advances in gastroenterology

Published: March 24, 2026

Imaging endpoints in inflammatory bowel disease: current evidence and future directions for ultrasound and MRI.

Imaging endpoints in inflammatory bowel disease: current evidence and future directions for ultrasound and MRI.

Journal: BMC medicine

Published: March 16, 2026

IOlBD evidence-based consensus on the use of artificial intelligence for assessment of endoscopic and histologic endpoints in clinical trials of inflammatory bowel disease.

IOlBD evidence-based consensus on the use of artificial intelligence for assessment of endoscopic and histologic endpoints in clinical trials of inflammatory bowel disease.

Journal: Journal of Crohn's & colitis

Published: March 09, 2026

Advancing Equity and Patient Partnership in Clinical Trials for Inflammatory Bowel Disease: A Model for Inclusive Trial Design.

Advancing Equity and Patient Partnership in Clinical Trials for Inflammatory Bowel Disease: A Model for Inclusive Trial Design.

Journal: Clinical and experimental gastroenterology

Published: March 03, 2026

IOIBD: the International Organization for the Study of Inflammatory Bowel Disease.

IOIBD: the International Organization for the Study of Inflammatory Bowel Disease.

Journal: Therapeutic advances in gastroenterology

Published: February 15, 2026

Combining Guselkumab with Upadacitinib Is Safe and Effective in the Treatment of Medically Complex Inflammatory Bowel Disease.

Combining Guselkumab with Upadacitinib Is Safe and Effective in the Treatment of Medically Complex Inflammatory Bowel Disease.

Journal: Digestive diseases and sciences

Published: February 12, 2026

Erratum to: New Eczematous Eruption in Patients With Inflammatory Bowel Disease Who Stop Janus Kinase Inhibitors.

Erratum to: New Eczematous Eruption in Patients With Inflammatory Bowel Disease Who Stop Janus Kinase Inhibitors.

Journal: The American journal of gastroenterology

Published: February 05, 2026

Impact of Upadacitinib on Cardiovascular Events and Lipid Values in Older Inflammatory Bowel Disease Patients With Baseline Cardiovascular Risk.

Impact of Upadacitinib on Cardiovascular Events and Lipid Values in Older Inflammatory Bowel Disease Patients With Baseline Cardiovascular Risk.

Journal: The American journal of gastroenterology

Published: January 26, 2026

Showing 1-12 of 553

Last Updated: 09/26/2026